ARGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the investor's beginner knowledge level, long-term strategy, and available capital, Argenx SE (ARGX) is a good buy. The company shows strong revenue growth, positive analyst sentiment, and promising product pipeline developments, making it a solid investment for long-term growth.
The stock is currently oversold with an RSI of 12.293, indicating potential for a rebound. The MACD histogram is negative and expanding, suggesting bearish momentum. Key support is at $735.933, and the stock is trading near this level, which could act as a strong entry point for long-term investors.
Strong Q4 earnings with revenue growth of 74.12% YoY, driven by VYVGART sales.
Positive Phase 3 trial results for VYVGART in ocular myasthenia gravis.
FDA priority review for VYVGART label expansion.
Analysts maintain high price targets and positive outlooks, with expectations of continued growth and market expansion.
Net income and EPS declined YoY, indicating increased operational expenses.
MACD and other technical indicators suggest short-term bearish momentum.
Gross margin slightly declined, reflecting higher costs.
In Q4 2025, revenue increased by 74.12% YoY to $1.29 billion, driven by strong demand for VYVGART. However, net income dropped by 31.16% YoY to $532.95 million, and EPS decreased by 30.98% to $8.02. Gross margin slightly declined to 88.36%.
Analysts remain highly optimistic, with multiple firms maintaining Buy or Outperform ratings. Price targets range from $867 to $1,247, reflecting confidence in the company's growth trajectory and product pipeline. Analysts highlight the strong uptake of VYVGART and the company's robust R&D pipeline as key drivers for future growth.
